- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03236090
Effect of Vivomixx® on Neuroinflammation in Patients Withs Cirrhosis
Study of the Effect of Vivomixx® on Neuroinflammation Ans Systemic Inflammatory Response in Patients With Cirrhosis
Study Design:
Double-blind randomized placebo-controlled clinical trial
Study Duration:
2 years
Study Center:
Single center Hospital de la Santa Creu i Sant Pau, Barcelona
Objectives:
To assess the effect of Vivomixx® on neuroinflammation and systemic inflammatory response in patients with cirrhosis
Study Overview
Detailed Description
Study variables Main variables
- Neuroinflammation
- Systemic inflammatory response Secondary variables
- Cognitive function
- Bacterial translocation
- Intestinal barrier
- Systemic oxidative damage
- Time until SBP or other bacterial infection resolution in patients with infections
- Incidence of complications of cirrhosis and mortality during the study 40 patients, 20 and 30 in each of the two substudies, respectively Diagnosis and Main Inclusion Criteria
Decompensated patients with cirrhosis:
- Outpatients with refractory ascites (substudy 1) (n=20)
- Patients hospitalized because bacterial infection (substudy 2) (n=30)
Study Product:
Vivomixx®sachets containing 450 x 109 bacteria, 2 every 12 hours (n=25), or placebo (n=25)
Duration of administration:
30 days Follow up The following patients' assessments will be performed: in substudy 1 at baseline and at the end of the treatment (30 days), and in substudy 2 at baseline, on day 1, day 2, day 3, day 7, at infection resolution, and at discharge or day 30.
Clinical and analytical assessments will be performed every three months after the end of the study Comparator Placebo (we evaluate the probiotic Vivomixx® vs placebo as adjunctive in addition to the standard of care) Statistical Methodology Fisher's exact test for categorical variables and Student's "t" test and Mann-Whitney and Wilcoxon tests for quantitative variables. Correlations will be assessed by Spearman test. A two-sided p value <0.05 will be considered statistically significant
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Barcelona, Spain, 08025
- Hospital de la Santa Creu i Sant Pau
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Outpatients with cirrhosis and refractory ascites according to current definition (29) (substudy 1), and hospitalized patients with cirrhosis and an episode of bacterial infection (substudy 2) at Hospital de la Santa Creu i Sant Pau.
Cirrhosis will be diagnosed by clinical, analytical and ultrasonographic findings or by liver biopsy. SBP will be diagnosed by an ascitic fluid neutrophil count > 250/mm3 with or without positive culture (28). Bacteremia, urinary infections, pneumonia, cellulitis, other bacterial infections and possible or suspected infections will be diagnosed according to current guidelines (13,14,28). All patients with SBP, bacteremia or pneumonia will be included. However patients with urinary infections, cellulitis or suspected infection these non-SBP infections will be required to fulfil the following requirements: at least two criteria of SIRS (systemic inflammatory response syndrome) (Annex I) (30) and CRP (C-reactive protein) >= 10 mg/dl (28).
Exclusion Criteria:
- Advanced hepatocellular carcinoma (beyond Milan's criteria) or any other malignancy determining a poor short-term prognosis.
- Advanced liver insufficiency [MELD (model for end-stage liver disease) >25].
- Marked symptomatic comorbidities (neurological, cardiac, pulmonary, renal, psychiatric, HIV infection).
- Septic shock, ileus, need for tracheal intubation or intensive care unit.
- Immunomodulatory drugs.
- In substudy 1, any infection at inclusion in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Outpatients with refractory ascites
20 consecutive outpatients with cirrhosis and refractory ascites Vivomixx®sachets containing 450 x 109 bacteria, 2 every 12 hours (n=25), or placebo (n=25)
|
Vivomixx®sachets containing 450 x 109 bacteria, 2 every 12 hours (n=25), or placebo (n=25)
|
Active Comparator: Patients hospitalized because bacterial infection
30 consecutive patients with cirrhosis and bacterial infections.
All patients will receive endovenous antibiotics and, only in the case of patients with SBP, also intravenous albumin Vivomixx®sachets containing 450 x 109 bacteria, 2 every 12 hours (n=25), or placebo (n=25)
|
Vivomixx®sachets containing 450 x 109 bacteria, 2 every 12 hours (n=25), or placebo (n=25)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in neuroinflammation
Time Frame: Change from baseline at 30 days
|
For substudy 1, neuroinflammation will be measured by MRI at baseline and 30 days
|
Change from baseline at 30 days
|
Change in neuroinflammation
Time Frame: Change from baseline at 3 days
|
For substudy 2, neuroinflammation will be measured by MRI at baseline and 3 days
|
Change from baseline at 3 days
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IIBSP-VIV-2016-109
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cirrhosis, Liver
-
Postgraduate Institute of Medical Education and...Society for the Study of Liver Diseases, Chandigarh ( India )UnknownDecompensated Cirrhosis of LiverIndia
-
SUUMC Central Military Hospital Dr Carol DavilaRecruiting
-
The Cleveland ClinicRecruiting
-
The Cleveland ClinicRecruitingCirrhosis, LiverUnited States
-
University of PittsburghNational Institute on Drug Abuse (NIDA)CompletedCirrhosis, LiverUnited States
-
Beth Israel Deaconess Medical CenterAmerican Association for the Study of Liver Diseases FoundationCompleted
-
Asian Institute of Gastroenterology, IndiaCompletedCirrhosis, LiverIndia
-
Sherief Abd-ElsalamUnknown
-
The Second Affiliated Hospital of Chongqing Medical...RecruitingFibrosis, Liver | Cirrhosis, LiverChina
Clinical Trials on Vivomixx
-
Singapore General HospitalUnknownSystemic SclerosisSingapore
-
Centre Hospitalier Universitaire de NiceRecruitingNeurocognitive Disorders | HIVFrance
-
Lund UniversityCompleted
-
University of Roma La SapienzaUnknownHIV | Anal DysplasiaItaly
-
University of Modena and Reggio EmiliaUnknownExercise Addiction | Dietary Modification | High-Risk Pregnancy | Gestational Diabetes Mellitus in Pregnancy, Diet- ControlledItaly
-
Fundació Institut de Recerca de l'Hospital de la...WithdrawnSpontaneous Bacterial PeritonitisSpain
-
IRCCS Fondazione Stella MarisMinistry of Health, Italy; Istituto di Fisiologia Clinica CNRCompletedAutism Spectrum DisorderItaly
-
Chinese University of Hong KongNot yet recruitingPregnancy Related | Microtia | Neonatal Jaundice
-
Hvidovre University HospitalUniversity of Copenhagen; Statens Serum InstitutCompletedObesity | Pregnancy | Gestational Diabetes MellitusDenmark
-
International Centre for Diarrhoeal Disease Research...Bill and Melinda Gates FoundationRecruitingEnvironmental Enteric Dysfunction | Gut Microbiota DysbiosisBangladesh